NO20062292L - Fremgangsmate for behandling av transplantasjonsavstoting - Google Patents

Fremgangsmate for behandling av transplantasjonsavstoting

Info

Publication number
NO20062292L
NO20062292L NO20062292A NO20062292A NO20062292L NO 20062292 L NO20062292 L NO 20062292L NO 20062292 A NO20062292 A NO 20062292A NO 20062292 A NO20062292 A NO 20062292A NO 20062292 L NO20062292 L NO 20062292L
Authority
NO
Norway
Prior art keywords
transplant rejection
procedure
treating transplant
treating
compound
Prior art date
Application number
NO20062292A
Other languages
English (en)
Norwegian (no)
Inventor
Paul Steven Changelian
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20062292L publication Critical patent/NO20062292L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
NO20062292A 2003-12-17 2006-05-19 Fremgangsmate for behandling av transplantasjonsavstoting NO20062292L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53118003P 2003-12-17 2003-12-17
PCT/IB2004/004034 WO2005060972A2 (en) 2003-12-17 2004-12-06 Pyrrolo [2,3-d] pyrimidine compounds for treating transplant rejection

Publications (1)

Publication Number Publication Date
NO20062292L true NO20062292L (no) 2006-06-14

Family

ID=34710208

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062292A NO20062292L (no) 2003-12-17 2006-05-19 Fremgangsmate for behandling av transplantasjonsavstoting

Country Status (17)

Country Link
US (1) US20050159433A1 (ko)
EP (1) EP1734967A2 (ko)
JP (1) JP2007514729A (ko)
KR (1) KR20060096153A (ko)
CN (1) CN1893952A (ko)
AU (1) AU2004305317A1 (ko)
BR (1) BRPI0417803A (ko)
CA (1) CA2549485A1 (ko)
CO (1) CO5700767A2 (ko)
IL (1) IL175812A0 (ko)
MX (1) MXPA06007002A (ko)
NO (1) NO20062292L (ko)
RU (1) RU2006120956A (ko)
SG (1) SG133602A1 (ko)
TW (1) TW200529853A (ko)
WO (1) WO2005060972A2 (ko)
ZA (1) ZA200604888B (ko)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001042246A2 (en) 1999-12-10 2001-06-14 Pfizer Products Inc. PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
EP1572213A1 (en) 2002-11-26 2005-09-14 Pfizer Products Inc. Method of treatment of transplant rejection
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
EP1910358A2 (en) 2005-07-14 2008-04-16 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
EP2251341A1 (en) 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
US20070149506A1 (en) 2005-09-22 2007-06-28 Arvanitis Argyrios G Azepine inhibitors of Janus kinases
TWI468162B (zh) 2005-12-13 2015-01-11 英塞特公司 作為傑納斯激酶（ＪＡＮＵＳ ＫＩＮＡＳＥ）抑制劑之經雜芳基取代之吡咯并〔２，３-ｂ〕吡啶及吡咯并〔２，３-ｂ〕嘧啶
GB0605691D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic Compounds
US8513270B2 (en) 2006-12-22 2013-08-20 Incyte Corporation Substituted heterocycles as Janus kinase inhibitors
SG10201509887UA (en) 2007-06-13 2016-01-28 Incyte Corp Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
ES2602577T3 (es) 2008-03-11 2017-02-21 Incyte Holdings Corporation Derivados de azetidina y ciclobutano como inhibidores de JAK
RU2493157C2 (ru) * 2008-08-20 2013-09-20 Пфайзер Инк. ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА
EP2421867B1 (en) 2009-04-20 2015-09-02 Auspex Pharmaceuticals, Llc Piperidine inhibitors of janus kinase 3
SG176111A1 (en) 2009-05-22 2011-12-29 Incyte Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
EA025520B1 (ru) 2009-05-22 2017-01-30 Инсайт Холдингс Корпорейшн N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
CN102574857B (zh) 2009-07-08 2015-06-10 利奥制药有限公司 作为jak受体和蛋白酪氨酸激酶抑制剂的杂环化合物
WO2011028685A1 (en) 2009-09-01 2011-03-10 Incyte Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US8486902B2 (en) 2009-10-09 2013-07-16 Incyte Corporation Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
MX347851B (es) 2010-03-10 2017-05-16 Incyte Corp Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
EP2574168B9 (en) 2010-05-21 2016-10-05 Incyte Holdings Corporation Topical formulation for a jak inhibitor
WO2012068450A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
CN103298817A (zh) * 2011-01-07 2013-09-11 利奥制药有限公司 作为蛋白酪氨酸激酶抑制剂的新磺酰胺哌嗪衍生物及其药物用途
AU2012219395B2 (en) 2011-02-18 2017-05-25 Incyte Corporation mTOR/JAK inhibitor combination therapy
EP2688890B1 (en) 2011-03-22 2017-08-30 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
CA2839767A1 (en) 2011-06-20 2012-12-27 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
WO2013023119A1 (en) 2011-08-10 2013-02-14 Novartis Pharma Ag JAK P13K/mTOR COMBINATION THERAPY
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
US9593115B2 (en) 2012-09-21 2017-03-14 Advinus Therapeutics Ltd. Substituted fused tricyclic compounds, compositions, and medicinal applications thereof
BR112015010663B1 (pt) 2012-11-15 2022-12-06 Incyte Holdings Corporation Formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo
CN103896826B (zh) * 2012-12-26 2016-08-03 上海朴颐化学科技有限公司 氮保护的(3r,4r)-3-甲氨基-4-甲基哌啶的不对称合成方法、相关中间体及原料制备方法
WO2014102826A1 (en) * 2012-12-28 2014-07-03 Glenmark Pharmaceuticals Limited; The present invention relates to process for the preparation of tofacitinib and intermediates thereof.
CN105189509B (zh) 2013-03-06 2017-12-19 因赛特公司 用于制备jak抑制剂的方法及中间体
RS60469B1 (sr) 2013-08-07 2020-07-31 Incyte Corp Dozni oblici sa produženim oslobađanjem za jak1 inhibitor
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
CN104059016A (zh) * 2014-06-20 2014-09-24 湖南天地恒一制药有限公司 制备托法替布的中间体及所述中间体的制备方法
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
WO2019152374A1 (en) 2018-01-30 2019-08-08 Incyte Corporation Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
MX2022012285A (es) 2018-03-30 2023-08-15 Incyte Corp Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US53782A (en) * 1866-04-10 Improvement in nut-machines
WO2001042246A2 (en) * 1999-12-10 2001-06-14 Pfizer Products Inc. PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
EP1572213A1 (en) * 2002-11-26 2005-09-14 Pfizer Products Inc. Method of treatment of transplant rejection

Also Published As

Publication number Publication date
KR20060096153A (ko) 2006-09-07
CO5700767A2 (es) 2006-11-30
BRPI0417803A (pt) 2007-04-10
US20050159433A1 (en) 2005-07-21
AU2004305317A1 (en) 2005-07-07
IL175812A0 (en) 2008-04-13
CA2549485A1 (en) 2005-07-07
JP2007514729A (ja) 2007-06-07
MXPA06007002A (es) 2006-08-31
SG133602A1 (en) 2007-07-30
EP1734967A2 (en) 2006-12-27
WO2005060972A2 (en) 2005-07-07
RU2006120956A (ru) 2008-01-27
CN1893952A (zh) 2007-01-10
TW200529853A (en) 2005-09-16
WO2005060972A3 (en) 2005-10-20
ZA200604888B (en) 2007-11-28

Similar Documents

Publication Publication Date Title
NO20062292L (no) Fremgangsmate for behandling av transplantasjonsavstoting
BR0316487A (pt) Método todo de tratamento da rejeição de transplantes
NO20044995L (no) Heterosykliske forbindelser
NO20051600L (no) 1,4-disubstituerte piperidinderivater og anvendelse derav som 11-betaHSD1 inhibitorer
DE60334536D1 (de) Furylverbindungen
NO20052787D0 (no) N-alkyl-4-metylenamino-3-hydroksy-2-pyridoner som antimikrobielle midler
NO20075066L (no) Farmasoytisk sammensetning som inneholder isoflavoner
NO20034661L (no) Nociceptin-analoger
NO20063576L (no) 1,3-dioksanederivativer og analoge forbindelser for behandling av fedme og diabetes
DE60333746D1 (de) Thienylverbindungen
NO20044767L (no) Farmasoytisk formulering med modifisert frigjoring
NO20062629L (no) Oksazolderivater av tetrackliner
ATE373474T1 (de) Substituierte 2-aminotetraline zur behandlung von depressionen
NO331012B1 (no) N-sulfonyl-4-metylenamino-3-hydroksy-2-pyridoner som antimikrobielle midler
NO20052182L (no) Nye forbindelser
AR024158A1 (es) Compuestos antibacterianos
MX2008001778A (es) Combinacion de un agente hipnotico y un compuesto de bis arilo y heteroarilo sustituido y aplicacion terapeutica de la misma.
ATE516031T1 (de) Verbindungen gegen krebs
NO20080144L (no) Spiro-benzimidazoler som inhibitorer av magesyre og sekresjon
FI970279A (fi) Orgaanisia yhdisteitä
UY29012A1 (es) "oxazolididonas y composiciones y metodos relacionados"
HRP20090187T1 (en) Bengamide derivatives and use thereof for the treatment of cancer
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
NO20062307L (no) Spirofuropyridinarylderivater
NO20055097L (no) Krystallinske N-formyl-hydroksylaminforbindelser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application